| Patent application number | Description | Published |
|---|
| 20090177104 | System and Method for Distinguishing Among Cardiac Ischemia, Hypoglycemia and Hyperglycemia Using an Implantable Medical Device - Techniques are described for detecting ischemia, hypoglycemia or hyperglycemia based on intracardiac electrogram (IEGM) signals. Ischemia is detected based on a shortening of the interval between the QRS complex and the end of a T-wave (QTmax), alone or in combination with a change in ST segment elevation. Alternatively, ischemia is detected based on a change in ST segment elevation combined with minimal change in the interval between the QRS complex and the end of the T-wave (QTend). Hypoglycemia is detected based on a change in ST segment elevation along with a lengthening of either QTmax or QTend. Hyperglycemia is detected based on a change in ST segment elevation along with minimal change in QTmax and in QTend. By exploiting QTmax and QTend in combination with ST segment elevation, changes in ST segment elevation caused by hypo/hyperglycemia can be properly distinguished from changes caused by ischemia. | 07-09-2009 |
| 20090177105 | System and Method for Distinguishing Among Cardiac Ischemia, Hypoglycemia and Hyperglycemia Using an Implantable Medical Device - Techniques are described for detecting ischemia, hypoglycemia or hyperglycemia based on intracardiac electrogram (IEGM) signals. Ischemia is detected based on a shortening of the interval between the QRS complex and the end of a T-wave (QTmax), alone or in combination with a change in ST segment elevation. Alternatively, ischemia is detected based on a change in ST segment elevation combined with minimal change in the interval between the QRS complex and the end of the T-wave (QTend). Hypoglycemia is detected based on a change in ST segment elevation along with a lengthening of either QTmax or QTend. Hyperglycemia is detected based on a change in ST segment elevation along with minimal change in QTmax and in QTend. By exploiting QTmax and QTend in combination with ST segment elevation, changes in ST segment elevation caused by hypo/hyperglycemia can be properly distinguished from changes caused by ischemia. | 07-09-2009 |
| 20090270936 | IMPLANTABLE MEDICAL DEVICE WITH COORDINATED VENTRICULAR OVERDRIVE AND TRIGGER MODE PACING - A method and system are provided for providing coordinated ventricular overdrive and triggered pacing through an implantable system. A lead senses signals from a heart to obtain sensed signals representative of tachycardia occurring in at least one chamber of the heart. The lead includes an electrode. A control module detects tachycardia in at least one chamber of the heart and based thereon, initiates an overdrive pacing mode and a triggered pacing mode. The control module controls delivery of overdrive pacing pulses through the electrode to a first chamber of the heart in accordance with the overdrive pacing mode. The control module controls delivery of a triggered pacing pulse through the electrode to the first chamber of the heart in accordance with the triggered pacing mode. The triggered pacing pulse is temporally interspersed with the overdrive pacing pulses. The triggered pacing pulse may be delivered at a time that is independent of, and unrelated to, the timing of the overdrive pacing pulses. | 10-29-2009 |
| 20100249862 | System and Method for Controlling Ventricular Pacing During AF Based on Underlying Ventricular Rates Using an Implantable Medical Device - Techniques are provided for controlling ventricular pacing during an episode of atrial fibrillation (AF) for use by a pacemaker, implantable cardioverter-defibrillator (ICD) or other implantable medical device. In one example, upon detection of AF, the underlying intrinsic ventricular rate of the patient is determined prior to delivering any ventricular pacing. Then, a ventricular pacing procedure—such as dynamic ventricular overdrive (DVO) pacing—is activated to reduce ventricular rate variability to mitigate the adverse effects of AF. The ventricular pacing procedure employed during AF is controlled based on a maximum ventricular rate set relative to the underlying intrinsic ventricular rate so as to keep an overall ventricular rate below the maximum rate. | 09-30-2010 |
| 20100280348 | METHOD AND IMPLANTABLE SYSTEM FOR BLOOD-GLUCOSE CONCENTRATION MONITORING USING PARALLEL METHODOLOGIES - In an implantable medical device for monitoring glucose concentration in the blood, a blood-glucose concentration analysis is performed using correlations of blood-glucose concentration with measures of metabolic oxygen consumption including oxymetric, and/or temperature. Analysis of electrocardiographic data is used in a parallel method to detect and/or confirm the onset and/or existence and/or extent of hypoglycemia and/or hyperglycemia. Blood-glucose concentration calculation is enhanced by using the combination of the oxygen metabolism analysis and electrocardiographic analysis. | 11-04-2010 |
